Mulpleo acts on the haematopoietic stem cells and on the transmembrane domain of human thrombopoietin (TPO) receptors expressed in megakaryocytes.1
This stimulates megakaryocyte proliferation and differentiation via a signal transduction pathway similar to endogenous TPO, leading to thrombocytopoiesis and increased platelet count in patients.1
Mulpleo binds to TPO receptors at all stages of thrombocytopoiesis2
Adapted from Kaushansky K, 1998.²
References
Mulpleo (lusutrombopag) Summary of Product Characteristics.
Kaushansky K. N Engl J Med. 1998;339(11):746–754.
Read about Mulpleo’s proven efficacy across its clinical trials.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyse site usage and assist in our marketing efforts.
Accept All Cookies Manage settingsManage Consent Preferences
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
These cookies allow us to count visits and traffic sources, so we can measure and improve the performance of our site. They help us know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies, we will not know when you have visited our site.
Disable Analytics Cookies Return to sitePP-UK-LUS-0315. Date of preparation: January 2023.